On this page
What SS-31 Does at the Mitochondrial Membrane: Cardiolipin Stabilisation Explained
SS-31 (also known as elamipretide, and under earlier development designations Bendavia and MTP-131) is a synthetic tetrapeptide with an unusual sequence: D-arginine, dimethylated tyrosine, lysine, and phenylalanide amide. It was developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College in the early 2000s as part of a systematic effort to design peptides that would accumulate in the inner mitochondrial membrane.
The mechanism that makes SS-31 distinctive in its class is cardiolipin binding. Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane, where it is essential for cristae architecture (the internal folded structures that house the respiratory chain) and for the assembly and stability of the supercomplexes formed by respiratory-chain Complexes I, III and IV. In aged and stressed mitochondria, cardiolipin becomes oxidised and disorganised, and the cristae collapse. Respiratory supercomplex assembly deteriorates, electron-transport-chain efficiency falls, and ATP production declines.
SS-31 binds cardiolipin selectively, protects it from peroxidation, and stabilises the curvature of cristae membranes. The downstream consequence is preservation of supercomplex assembly and restoration of electron-transport-chain efficiency. Critically, SS-31 does not act as a conventional antioxidant — it does not scavenge reactive oxygen species through redox chemistry. Its activity is structural. By preserving the membrane architecture that allows respiratory complexes to function normally, it reduces the generation of reactive oxygen species as a downstream consequence of restored efficiency.
This mechanistic distinction matters. Conventional antioxidant supplementation has a poor track record in clinical ageing trials, partly because ROS generation in aged mitochondria is a structural-efficiency problem rather than simply an excess-substrate problem. SS-31's structural approach is conceptually better matched to the underlying biology.
The Siegel et al. 2013 Result: 8 Days to Restore Aged-Muscle Physical Performance
The preclinical result that established SS-31 as a serious longevity-biology research tool was published in Aging Cell in 2013 by Siegel, Kruse, Percival and colleagues. The study used aged C57BL/6 mice (a well-validated ageing model) and administered SS-31 for eight days.
The results were stark. In aged animals receiving SS-31, skeletal-muscle ATP production was restored to levels comparable to young controls. Redox state in muscle tissue normalised. Fatigue resistance improved to match young-muscle performance on treadmill testing. Eight days of treatment produced a restoration of mitochondrial and physical function that years of normal ageing had eroded.
The speed of the effect is mechanistically informative. Structural stabilisation of a membrane-bound component can produce rapid downstream benefits that are not contingent on gene expression changes, protein synthesis, or remodelling of tissue architecture. If the primary defect in aged mitochondria is cardiolipin-mediated cristae disorder, then directly correcting that structural problem can produce rapid functional recovery. This is distinct from, say, inducing mitochondrial biogenesis, which takes weeks to produce meaningful changes in mitochondrial number and capacity.
MMPOWER Programme: Phase II Results vs. Phase III Readouts — Why They Diverged
The MMPOWER clinical programme, conducted by Stealth BioTherapeutics, studied SS-31 in patients with primary mitochondrial myopathy — a genetic condition in which mitochondrial function is impaired by mutations in the respiratory chain, producing progressive muscle weakness. The indication was chosen in part because it offered a clinically defined population with measurable mitochondrial dysfunction.
Phase II results were encouraging. Patients receiving elamipretide showed improvements in six-minute-walk distance (a validated functional endpoint for neuromuscular conditions) and the safety profile was clean, with injection-site reactions the most common adverse event.
Phase III results were less clear. The MMPOWER-3 trial, a randomised placebo-controlled study of 218 patients published in Neurology in 2020 by Karaa and colleagues, did not meet its primary endpoint of six-minute-walk distance improvement at week 24. The result was statistically negative on that primary measure.
Several factors make this divergence interpretable rather than simply dismissive of the compound. Primary mitochondrial myopathy is a heterogeneous condition — patients with different mutations may have different threshold responses to cardiolipin-targeted therapy. The six-minute-walk test is a meaningful but imprecise endpoint that captures ambulatory capacity without necessarily reflecting the mitochondrial-efficiency improvements the compound produces. And the phase III trial did show improvement in patient-reported fatigue outcomes on active treatment, suggesting that something biologically real was happening even if it was not large enough to move the primary endpoint significantly.
The ReCLAIM Trial in Dry AMD: Mitochondrial Peptides and Ocular Biology
Elamipretide was also studied in dry age-related macular degeneration (AMD), a condition characterised by progressive retinal degeneration in which mitochondrial dysfunction in retinal pigment epithelial cells is a well-established pathological feature. The biological rationale for a mitochondrial-targeting peptide in this setting is coherent: the retina is one of the highest-energy-demand tissues in the human body, and retinal pigment epithelial cells have an unusually high density of mitochondria.
The ReCLAIM programme examined both local (intravitreal) and systemic administration. Published results showed signals of reduced progression and improved functional measures in subgroups of patients, but regulatory approval was not achieved within the initial development timeline. The programme illustrates both the breadth of mitochondrial biology relevant to ageing-adjacent conditions and the difficulty of demonstrating benefit in heterogeneous, slowly progressing conditions with existing variability in natural history.
What a Negative Primary Endpoint With Positive Patient-Reported Outcomes Tells Us
The MMPOWER-3 result is worth examining as a methodological case study. The discordance between a negative primary endpoint on a functional walking test and positive patient-reported fatigue outcomes is a pattern that appears in multiple clinical trials in conditions where mitochondrial dysfunction is relevant.
One interpretation is that patient-reported outcomes are more sensitive to the actual biological change being produced: fatigue, which patients experience directly and continuously, captures improvements in metabolic efficiency that a discrete once-every-six-months walking test misses. A second interpretation is that the patient-reported benefit is a placebo effect that was not adequately controlled in the measurement. A third is that the treatment produces real benefits in the domains patients care most about — energy, daily function, symptom burden — without producing measurable changes in peak-performance metrics.
What the trial cannot support is a conclusion that the compound does nothing. The negative primary endpoint means the compound did not meet the agreed regulatory threshold for approval in that indication, which is a specific and important regulatory conclusion. It does not mean the mechanism is irrelevant to mitochondrial ageing biology or that the safety profile is concerning.
Research-Grade SS-31 vs. Clinical Elamipretide: The Same Molecule, Different Context
The distinction between research-grade SS-31 and clinical-trial elamipretide is the same distinction that applies across this field: same molecular structure, different regulatory context, different quality standards, and different intended use. The SS-31 elamipretide: cardiolipin mechanism and clinical trial summary sets out this distinction in detail.
For researchers working outside clinical-trial settings, SS-31's value is the unusually well-characterised mechanistic and pharmacokinetic profile that the clinical-stage programme has generated. Plasma half-life, tissue distribution, and adverse-event patterns are documented at a level of detail that most research peptides lack entirely. That prior knowledge substantially reduces the uncertainty involved in preclinical research programme design and makes SS-31 one of the most tractable tools in the longevity-peptide toolkit, irrespective of where its clinical development ultimately lands.




